United Kingdom approves AstraZeneca's Covid-19 vaccine for emergency use

Пятница, 01 Янв, 2021

AstraZeneca did not specify which dose regime had been approved, but researchers said approval was the most important thing.

J&J had kicked off a final trial of the single-shot COVID-19 vaccine in September.

Instead, Pirmohamed said a higher success rate may be due to a longer gap between the administration of the first and second shots.

"And we feel that that result may be related to that interval, rather than the dose itself", he said.

The UK government has reserved one fill and finish production line at Wockhardt's UK facility for its exclusive use for 18 months in order to guarantee the supply of vaccines required to fight against COVID-19.

The EMA says it has not yet received full data on the AstraZeneca vaccine and is unlikely to be able to approve it next month.

"We felt the results were not borne out by the full analysis", Munir Pirmohamed, a pharmacologist who chairs the U.K.'s Commission on Human Medicines (CHM) Expert Working Group-tasked with advising the CHM on potential COVID-19 vaccines-said in a media briefing Wednesday.

The country has ordered 100 million doses, enough for 50 million people.

"We will now move to vaccinate as many people as quickly as possible", tweeted British Prime Minister Boris Johnson.

The COVID-19 vaccine developed by British drugmaker AstraZeneca Plc and Oxford University will likely be authorized for emergency use in the United States in April, the chief adviser for the U.S. COVID-19 vaccine program said on Wednesday. "More than 600,000 people in the United Kingdom have been vaccinated with the Pfizer-BioNTech jab since Margaret Keenan became the first in the world to be given a Covid vaccine outside of a clinical trials".

Pfizer sounded cautious on the prospect of shifting the schedule of its second dose, noting it had not been evaluated on different dosing schedules.

It logged more than 1,000 daily deaths for the first time, authorities said Wednesday, as Chancellor Angela Merkel warned that the country's "difficult times" were going to last "for a good while yet". The shot can be deployed swiftly because it's is easier to transport and store than the Pfizer-BioNTech one, requiring only refrigerator temperatures rather than deep freezing.

The U.K.'s Vaccine Taskforce has outlined plans to test combinations of approved shots next year to see if a mix could boost immunity, the panel said this month.

"The MHRA have said that they will be publishing their assessment report".

General secretary Paul Donaldson said: "While a planned and orderly deployment of the Oxford vaccination including longer timelines makes epidemiological sense, the decision to throw a spanner in the works of the existing Pfizer rollout appears simply weird unless there is an unknown hitch in supply".

In a coronavirus data briefing marking the vaccine's approval in the UK, MHRA boss Dr Raine strongly insisted that "no corners, whatsoever" had been cut.

"More needs to be known because many points about these decisions remain unclear".